Norges Bank
SGMO

Norges Bank’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Norges Bank’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$84K – 2070
2019
Q4 		$84K Hold
10,000
– – ﹤0.01% 2073
2019
Q3 		$91K Hold
10,000
– – ﹤0.01% 2085
2019
Q2 		$108K Buy
+10,000
New +$106K ﹤0.01% 2086

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's SGMO Position: Q1 2020 in Review

Norges Bank sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2020, closing a stake of 10,000 shares — an estimated $84K sold.

Norges Bank first reported a position in SGMO in Q2 2019 and held it in 3 quarters. The position peaked at $108K in Q2 2019. 190 funds tracked by Wall St. Rank hold SGMO as of Q1 2020.

  • Norges Bank reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2020 after selling out during the quarter.
  • Norges Bank sold 10,000 SANGAMO THERAPEUTICS INC shares in Q1 2020, an estimated $84K.
  • Norges Bank first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 3 quarters.
  • Norges Bank's SANGAMO THERAPEUTICS INC position peaked at $108K in Q2 2019.
  • 190 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2020.

Based on Norges Bank's 13F filing for Q1 2020, filed 8 May 2020.